The results of ProHCL: Patient-reported outcomes in people living with type 1 diabetes on hybrid closed-loop insulin pump therapy − experiences from the NHS England pilot

AIMS: This study evaluated the impact of ≥3 months of HCL use on patient-reported outcomes (PROs) in PwT1D and their partners. METHODS: Participants enrolled on the NHS England HCL pilot were invited to take part in a mixed-methods study. Here, we present the results of the quantitative study. PwT1D completed online questionnaires, including INSPIRE (0-100), DTSQc (-18 to +18), System Usability Scale (0-100), and bespoke measures. Self-reported clinical data were collected. Optionally, partners completed the INSPIRE for partners questionnaire. RESULTS: A total of 125 PwT1D and 33 partners participated. PROs included: INSPIRE 88/100 (IQR 73-95) and DTSQc 17/18(14-18). In INSPIRE, >70 % strongly agree that HCL improved HbA1c, time in range and overall quality of life. In DTSQc, >70 % noted that their blood glucose levels had been unacceptably low/high much less of the time since starting HCL. However, 54.4 % reported increased alarm burden and 21.6 % information overload. People who found HCL harder to use based on the SUS score had lower INSPIRE, DTSQs and DTSQc scores and higher HbA1c than those who found HCL easier to use. CONCLUSIONS: HCL therapy is associated with improved PROs in PwT1D. However, system usability significantly influences outcomes, and alarm and data burden remain concerns.